The Latest Cardiac and Vascular News
Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019 Launch Commenced of VASCEPA® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication Management to Host Conference Call at 4:30 p.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) — […]
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® (icosapent ethyl) by the U.S. Food and Drug Administration (FDA) in December 2019. This […]
Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above Upper-End of Prior Guidance of $410 to $425 Million U.S. Sales Force Expansion On-Track for Doubling to 800 Sales Professionals in Early 2020 Full-Year 2020 Net Total Revenue Guidance Reiterated at $650 to $700 Million, Predominately from U.S. Sales […]
VASCEPA becomes the first and only Health Canada approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the studied high-risk patients approved for treatment Commercial launch expected in mid-February 2020 by Amarin’s commercial partner for Canada VASCEPA approval was supported by clinical results from the REDUCE-IT® trial which included […]
REDUCE-IT USA results, in prespecified subgroup analyses, showed cardiovascular risk reductions across all endpoints, including 30% relative risk reduction in all-cause mortality New analysis determined icosapent ethyl (Vascepa®) is highly cost-effective in patients from the REDUCE-IT study and, as is rarely found, may result in net healthcare cost-savings to patients, payers […]
This National-Level Recognition Follows EY’s New Jersey Regional Entrepreneur of The Year® Award Earlier in 2019 and Reflects Amarin’s Tremendous Business Growth While Helping to Improve Patient Healthcare DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced […]
Cardiovascular disease events like heart attacks, stroke and death affect millions of patients in the United States and are estimated to cost $500 billion annually Millions of high-risk patients with cardiovascular disease could benefit from this cost-effective therapy if expanded label receives FDA approval; PDUFA date is December 28 DUBLIN, […]
Prespecified Analysis of 3,146 Patients in the USA Enrolled in REDUCE-IT Showed 31% Relative Risk Reductions for First Occurrence of Both 5-Point MACE and 3-Point MACE Significant Reductions Shown in All Predefined Composite and Individual Cardiovascular Endpoints, Including Cardiovascular Death and All-Cause Mortality Tolerability and Safety Findings Consistent with Full […]
Record Revenue Levels and Preparations On-Track for Further Expansion Management to Host Conference Call at 7:30 a.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced financial results for the three and nine […]
Multiple Papers and Presentations Highlight REDUCE-IT and Vascepa® Potential Mechanisms of Action of Vascepa Becoming Better Understood American Heart Association References REDUCE-IT in Scientific Advisory BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 27, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today provided […]
